| Old Articles: <Older 25791-25800 Newer> |
|---|
 |
The Motley Fool
August 29, 2007
Jack Uldrich |
Big Blue Taps the Water IBM's plan to network the Hudson could lead to a river of opportunities. Investors, take note.   |
The Motley Fool
August 29, 2007
Jeremy MacNealy |
Another Unexciting Chapter at Borders Sales are strong, but the bookseller still sees a significant loss in the second-quarter. Investors, take note. |
The Motley Fool
August 29, 2007
Ryan Fuhrmann |
Foolish Forecast: Tiffany's Hot Ice The jewelry store icon is set to release second-quarter results. Investors, here is what you can expect to find. |
The Motley Fool
August 29, 2007
Tom Taulli |
MIPS Seeks an M&A Hit The digital chip company makes a major deal to reach a new market. Investors, take note. |
The Motley Fool
August 29, 2007
Brian Orelli |
Inverness Trades Stock for Revenue Inverness Medical Innovations announces plans to buy the biotech company Matritech, bringing to eight the total number of acquisitions Inverness has made in the past year and a half. |
The Motley Fool
August 29, 2007
Alyce Lomax |
Scorched EarthLink Did EarthLink's cost-cutting really give investors anything to cheer about? |
The Motley Fool
August 29, 2007
Mike Cianciolo |
Troubling Days at Tuesday Morning Profits plummet in the second quarter, but the retailer looks to a brighter tomorrow. Investors, take note. |
The Motley Fool
August 29, 2007
Rick Aristotle Munarriz |
Playing Games in China The9 looks to grow in China, but its earnings are going the wrong way. The Chinese online gaming specialist stumbled in its latest quarter, clocking in well below Wall Street expectations. |
The Motley Fool
August 29, 2007
Rich Duprey |
Medco's Potentially Perilous Purchase Is pharmacy-benefits manager Medco Health Solutions risking its own health by buying diabetes-testing supplier PolyMedica? The deal may end up being so expensive as to drain Medco's own performance. |
The Motley Fool
August 29, 2007
Brian Lawler |
PDL Lands in a Hazard The biopharma announces a dramatic shift following the failure of its lead drug. Shares of PDL are down only 19% this morning, presumably because the thought of a leaner and thriftier PDL with its royalty-generating potential is a welcome relief to some investors. |
| <Older 25791-25800 Newer> Return to current articles. |
